Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19076253 | 0.87 | MAPT (0.53) | S1PR1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL19084924 | 0.81 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL19084929 | 0.79 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL5638115 | 0.77 | MAPT (0.70) | MAPTRAB9ASMN1; SMN2TP53HDAC6 | |
| SCHEMBL7610004 | 0.77 | MAPT (0.81) | MAPTRAB9ASMN1; SMN2TP53HDAC6 | |
| SCHEMBL5642041 | 0.76 | MAPT (0.64) | MAPTRAB9ASMN1; SMN2TP53HDAC6 | |
| SCHEMBL19029332 | 0.75 | MAPT (0.61) | MAPTRAB9ASMN1; SMN2TP53HDAC6 | |
| SCHEMBL27170328 | 0.75 | MAPT (0.47) | S1PR1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL30791739 | 0.75 | MAPT (0.47) | S1PR1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL20897608 | 0.75 | MAPT (0.58) | S1PR1MAPTRAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300155-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300155-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | S1PR1 1435/4885MAPT 58/4885RAB9A 152/4885 |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | S1PR1 1435/4885MAPT 58/4885RAB9A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.